[HTML][HTML] Treatment resistance in psychiatry: state of the art and new directions
OD Howes, ME Thase, T Pillinger - Molecular psychiatry, 2022 - nature.com
Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …
associated with increased healthcare burden and costs up to ten-fold higher relative to …
Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia
JC Martel, S Gatti McArthur - Frontiers in pharmacology, 2020 - frontiersin.org
Dopamine receptors are widely distributed within the brain where they play critical
modulator roles on motor functions, motivation and drive, as well as cognition. The …
modulator roles on motor functions, motivation and drive, as well as cognition. The …
The clinical significance of duration of untreated psychosis: an umbrella review and random‐effects meta‐analysis
The idea that a longer duration of untreated psychosis (DUP) leads to poorer outcomes has
contributed to extensive changes in mental health services worldwide and has attracted …
contributed to extensive changes in mental health services worldwide and has attracted …
A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia
Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …
of patients do not show adequate improvement in positive symptoms with non-clozapine …
[HTML][HTML] Treatment-resistant schizophrenia: definition, predictors, and therapy options
CU Correll, OD Howes - The Journal of clinical psychiatry, 2021 - psychiatrist.com
Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …
Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies
Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
MC Lobo, TS Whitehurst, SJ Kaar, OD Howes - … & Biobehavioral Reviews, 2022 - Elsevier
Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …
new treatments. This narrative review compares the pharmacology, clinical trial data and …
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …